New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
11:15 EDTJNJJanssen enters license and R&D agreements with GlycoVaxyn AG
GlycoVaxyn AG announced that Janssen Pharmaceuticals, Inc. has signed an exclusive license agreement and entered into a three-year research and development collaboration to develop a multi-valent bacterial vaccine employing GlycoVaxyn's bio-conjugation technology. GlycoVaxyn will collaborate with JPI's affiliate, Crucell Holland BV, on the development of the multi-valent vaccine until proof-of-concept, after which JPI will be responsible for later-stage clinical studies and world-wide commercialization. The consideration to GlycoVaxyn includes an upfront payment, milestone payments, royalties as well as reimbursement of research and development expenses. Financial details of the agreement have not been disclosed. Janssen Pharmaceuticals is a pharmaceutical company of Johnson & Johnson.
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2015
10:52 EDTJNJFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information
November 18, 2015
08:11 EDTJNJIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
08:11 EDTJNJAduro Biotech receives milestone payment from Janssen
Aduro Biotech (ADRO) announced that it has received a milestone payment from Janssen Biotech (JNJ) for Aduro's submission of an Investigational New Drug, or IND, Application to the FDA for ADU-741, a LADD immunotherapy product candidate for the treatment of prostate cancer. The IND will enable Janssen, Aduro's license partner for ADU-741, to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741 in patients with metastatic castration-resistant prostate cancer.
November 16, 2015
14:38 EDTJNJGenmab confirms FDA approval of Darzalex
Subscribe for More Information
13:09 EDTJNJFDA approves Darzalex to treat multiple myeloma
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use